A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis

Letter Critical Care Medicine

COVID-19 Severity Index: A predictive score for hospitalized patients

I. Huespe et al.

MEDICINA INTENSIVA (2022)

Article Clinical Neurology

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Maria Pia Sormani et al.

Summary: This study compares the outcomes of COVID-19 in patients with multiple sclerosis (MS) in Italy with the expected outcomes in the general population. The risk of severe events, including hospitalization, ICU admission, and death, was found to be twice as high in the MS cohort compared to the age- and sex-matched Italian population. The increased risk was primarily associated with disease severity and comorbidities, but there was also a higher risk of hospitalization in patients on anti-CD20 therapies and a lower risk in patients on interferon.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Add to Collection

Article Clinical Neurology

COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis

Naghmeh Abbasi et al.

Summary: This study reveals that a small group of multiple sclerosis patients in Iran have vaccine hesitancy, which may increase their susceptibility to severe COVID-19. Physicians should inquire about patients' vaccination history and persuade them with scientific knowledge. The long-term consequences of not being vaccinated should be clarified to patients, especially those receiving immunosuppressive treatment.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Review Allergy

Risk factors for severe and critically ill COVID-19 patients: A review

Ya-dong Gao et al.

Summary: The severity factors of COVID-19 include age, gender, underlying health conditions such as hypertension, diabetes, obesity, and immunodeficiency, which may lead to complications like acute kidney injury. Various laboratory indicators and parameters can help monitor disease progression, while socioeconomic factors, lifestyle, and quality of healthcare also play a role in individual outcomes.

ALLERGY (2021)

Add to Collection

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

The MuSC-19 study: The Egyptian cohort

Magd Zakaria et al.

Summary: This study reported the severity of COVID-19 in Egyptian patients with MS, finding headache as a significant symptom associated with severity. There was no association found between DMDs and severe outcomes of COVID-19.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Coronavirus disease 2019 in Latin American patients with multiple sclerosis

Yara D. Fragoso et al.

Summary: Patients with multiple sclerosis (MS) who have coronavirus disease 2019 (COVID-19) may face increased risks due to their neuroimmune condition and long-term immunomodulatory therapies. A study of 73 MS patients with confirmed COVID-19 in Latin America found that the use of anti-CD20 therapies was the only risk factor associated with hospitalization and death. Despite the small sample size, this study highlights the importance of considering therapeutic options for MS patients during the pandemic.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Medicine, General & Internal